Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
LUND (Sweden) - Immunovia invites to a teleconference (in English) for investors, analysts and media on Friday, February 14th, 2020 at 8:30 am CET. Immunovia will publish the company's Full Year 2019 report on February 14[th], 2020 at 8:00 am CET.
Mats Grahn, CEO will present Immunovia and comment on the interim report for the period Full Year 2019 Report followed by a Q&A session. Please call in a few minutes in advance.
To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:
Dial-in numbers:
Sweden: +46 (0) 8 50 520 424
United States: +1 212 999 6659
Austria: +43 (0) 12530807
Germany: +49 (0) 30 3001 90612
Denmark: +45 3271 4573
Switzerland: +41 (0) 22 592 7103
Spain: +34 91 787 0777
Netherlands: +31 (0) 20 794 8426
Norway: +47 2156 3318
France: +33 (0) 1 7037 7166
United Kingdom (standard international access): +44 (0) 20 3003 2666
Conference code:
(To provide to the operator): Immunovia
Webcast:
https://channel.royalcast.com/webcast/immunovia/20200214_1/
For more information, please contact:
Julie Silber, Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277
There will be an MP3-file available at Immunovia's webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 (https://immunovia.com/immray-pancan-d/prospective-studies-and-next-step/) and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
###